Halozyme

American biotechnology company

Logo of Halozyme Therapeutics

Halozyme Therapeutics, Inc. is an American biotechnology company focused on developing and commercializing products that target the extracellular matrix for the treatment of cancer, diabetes, and other diseases. The company is headquartered in San Diego, California.

History

Halozyme was founded in 1998 by Gregory I. Frost and Jonathan Lim. The company initially focused on developing recombinant human hyaluronidase enzymes. In 2004, Halozyme went public and began trading on the NASDAQ under the ticker symbol HALO.

Technology

Halozyme's core technology is based on the use of recombinant human hyaluronidase enzymes, which are designed to degrade hyaluronic acid in the extracellular matrix. This technology is used to facilitate the delivery of drugs and fluids, enhance the absorption and dispersion of injected drugs, and improve the efficacy of cancer treatments.

ENHANZE Technology

The company's proprietary ENHANZE technology platform is used to develop subcutaneous formulations of biologics and small molecules. ENHANZE utilizes the recombinant human hyaluronidase enzyme, rHuPH20, to temporarily degrade hyaluronic acid, allowing for increased permeability and absorption of co-administered drugs.

Products and Collaborations

Halozyme has developed several products and has entered into collaborations with major pharmaceutical companies to apply its ENHANZE technology to their drug candidates.

Approved Products

Halozyme's technology has been used in the development of several approved products, including:

• Hylenex: A formulation of recombinant human hyaluronidase used to enhance the absorption and dispersion of other injected drugs.
• Herceptin SC: A subcutaneous formulation of trastuzumab developed in collaboration with Roche.

Collaborations

Halozyme has established partnerships with several pharmaceutical companies, including:

• Roche
• Bristol-Myers Squibb
• Pfizer
• Janssen Pharmaceuticals

These collaborations focus on applying the ENHANZE technology to develop subcutaneous formulations of existing intravenous drugs, potentially improving patient convenience and compliance.

Research and Development

Halozyme continues to invest in research and development to expand the applications of its technology. The company is exploring new therapeutic areas and developing next-generation enzyme formulations to enhance drug delivery and efficacy.

Corporate Governance

Halozyme is led by a team of experienced executives and governed by a board of directors. The company's leadership is focused on advancing its technology platform and expanding its product pipeline through strategic partnerships and internal development efforts.

Related pages

• Biotechnology
• Pharmaceutical industry
• Drug delivery